Fig. 6
From: Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis
Crossreactive antibodies inhibit ELR+ CXC chemokine signaling in vitro. Residual activity of a human hCXCL1, hCXCL5, and hCXCL8 and b mouse mCXCL1 and mCXCL2 chemokines incubated with varying concentrations of SA129 (red), SA138 (blue), and SA157* (gray) fusions, and commercial neutralizing antibodies (Ab, white). The indicated values are the means of three independent experiments. c Plot displaying pKi versus the calculated pKD of SA129 (red), SA138 (blue), and SA157* (gray) fusions. Data are presented as mean (dots) ± s.e.m. (bars)
